TABLE 1

Therapies with sulfasalazine, salicylates, or PJ34 do not normalize the alterations in body weight, blood glucose, and GHb levels in experimentally diabetic rats

Body wt (g)Blood glucose (mg/dl)GHb (%)
9 months
    Normal609 ± 5876 ± 114.0 ± 0.2
    Diabetic304 ± 48*325 ± 30*9.0 ± 1.1*
    Diabetic + sulfasalazine300 ± 36*344 ± 1*9.9 ± 0.7*
3 months (experiment 1)
    Normal449 ± 20109 ± 123.7 ± 0.1
    Diabetic267 ± 31*281 ± 43*9.1 ± 1.2*
    Diabetic + sulfasalazine263 ± 30*314 ± 25*7.7 ± 1.3*
    Diabetic + sodium salicylate269 ± 29*299 ± 23*7.6 ± 0.5*
    Diabetic + buffered aspirin257 ± 24*314 ± 33*8.1 ± 1.1*
3 months (experiment 2)
    Normal458 ± 14122 ± 13.8 ± 0.2
    Diabetic276 ± 42*291 ± 39*9.2 ± 0.9*
    Diabetic + sulfasalazine256 ± 18*293 ± 1*9.2 ± 2.0*
    Diabetic + PJ34263 ± 28*287 ± 61*9.2 ± 1.1*

  • Data are means ± SD of 6–10 animals.

  • *

    * Significantly different from normal rats at P < 0.01 (ANOVA followed by Dunnett's test).